A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Inclusion Criteria: * Have type 2 diabetes * Have an HbA1c ≥7.5% to ≤10.5% at screening * Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening * Diet and exercise * Stable dose of metformin * Sodium-glucose cotransporter-2 (SGLT2) inhibitor * Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening * Have a BMI of 27 or greater at screening Exclusion Criteria: * Have any form of diabetes other than type 2 diabetes * Have a prior or planned surgical treatment for obesity, except prio…